ULTRAGENYX PHARMACEUTICAL INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$565.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-18.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-18
- ULTRAGENYX PHARMACEUTICAL INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$565.00M.
- ULTRAGENYX PHARMACEUTICAL INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$563.00M.
- ULTRAGENYX PHARMACEUTICAL INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$609.00M.
- ULTRAGENYX PHARMACEUTICAL INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$703.41M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$565.00M 10-K · filed 2026-02-18 | |
| 2024-12-31 | -$563.00M 10-K · filed 2026-02-18 | -$564.07M 10-K · filed 2025-02-19 |
| 2023-12-31 | -$609.00M 10-K · filed 2026-02-18 | -$608.17M 10-K · filed 2024-02-21 |
| 2022-12-31 | -$703.41M 10-K · filed 2025-02-19 | |
| 2021-12-31 | -$455.31M 10-K · filed 2024-02-21 | |
| 2020-12-31 | -$189.45M 10-K · filed 2023-02-17 | |
| 2019-12-31 | -$399.71M 10-K · filed 2022-02-15 | |
| 2018-12-31 | -$205.44M 10-K · filed 2021-02-12 | |
| 2017-12-31 | -$250.92M 10-K · filed 2020-02-14 | |
| 2016-12-31 | -$192.29M 10-K · filed 2019-02-20 | |
| 2015-12-31 | -$145.62M 10-K · filed 2018-02-21 | |
| 2014-12-31 | -$59.80M 10-K · filed 2017-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |